Pfizer Suffers Grim Q3, But Management Points To Future Growth Drivers
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer’s revenues fell 16% in the third quarter, as the pharma giant absorbed exclusivity losses including the loss of Lipitor, but management tried its best to highlight long-term growth drivers during a Nov. 1 conference call.